Index
By TNW
About Index
Trending news
Analyze
Pricing
Sign up or sign in
Alimera Sciences
Work at Alimera Sciences?
Add yourself to this profile
2934
Alimera Sciences
Biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals with a focus on the back of the eye, or retina.
Edit Profile
alimerasciences.com
Health Care
>
Medical
Technology
>
Biotechnology
Health Care
>
Medical
>
Pharmaceuticals
B2c
Founded in
2003
Raised
$61.5M
More info
Elsewhere
Companies in the same industry
Batu Biologics
Symbiomix
Pearl Therapeutics
F2G
Sirenas Marine Discovery
Ritter Pharmaceuticals, Inc.
Clontech Laboratories Inc
Prospective Research
Napo Pharmaceuticals
Esperion Therapeutics
Alexa global traffic share
Twitter followers
Overview
Funding
2
Add info
Latest funding
Post-IPO equity
$26,500,000
Post-IPO debt
$35,000,000
Employees
Team size
50+
Locations
HQ
United States
Headquarters
$26,500,000
Post-IPO equity
GlobeNewswire News Room
Alimera Sciences Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock
Batu Biologics
Symbiomix
Pearl Therapeutics
F2G
Sirenas Marine Discovery
Clontech Laboratories Inc
Prospective Research
Napo Pharmaceuticals